Soko Setoguchi

Soko Setoguchi

Auto-generated profile, based on publicly available information

Soko Setoguchi

Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
BBBenjamin A. Bates
Benjamin A. Bates
EAEhimare Akhabue
Ehimare Akhabue
MNMeghan M. Nahass
Meghan M. Nahass
AMAbhigyan Mukherjee
Abhigyan Mukherjee
EHEmily Hiltner
Emily Hiltner
SSSoko Setoguchi
Soko Setoguchi
Background: Heart failure (HF) is a leading cause of hospitalization in older adults. Medicare data have been used to assess HF outcomes. However, the validity of ICD-10 diagnosis codes (used since 2015) to identify acute HF hospitalization or distinguish reduced (heart failure with reduced ejection fraction) versus preserved ejection fraction (HFpEF) is unknown in Medicare data. Methods: Using Medicare data (2015–2017), we randomly sampled 200 HF hospitalizations with ICD-10 diagnosis codes for HF in the first/second claim position in a 1:1:2 ratio for systolic HF (I50.2), diastolic HF (I50.3), and other HF (I50.X). The primary gold standards included recorded HF diagnosis by a treating physician for HF hospitalization, ejection fraction (EF)≤50 for heart failure with reduced ejection fraction, and EF>50 for HFpEF. If the quantitative EF was not present, then qualitative descriptions of EF were used for heart failure with reduced ejection fraction/HFpEF gold standards. Multiple secondary gold standards were also tested. Gold standard data were extracted from medical records using standardized forms and adjudicated by cardiology fellows/staff. We calculated positive predictive values with 95% CIs. Results: The 200-chart validation sample included 50 systolic, 50 diastolic, 47 combined dysfunction, and 53 unspecified HF patients. The positive predictive values of acute HF hospitalization was 98% [95% CI, 95–100] for first-position ICD-10 HF diagnosis and 66% [95% CI, 58–74] for first/second-position diagnosis. Quantitative EF was available for ≥80% of patients with systolic, diastolic, or combined dysfunction ICD-10 codes. The positive predictive value of systolic HF codes was 90% [95% CI, 82–98] for EFs≤50% and 72% [95% CI, 60–85] for EFs≤40%. The positive predictive value was 92% [95% CI, 85–100] for HFpEF for EFs>50%. The ICD-10 codes for combined or unspecified HF poorly predicted heart failure with reduced ejection fraction or HFpEF. Conclusions: ICD-10 principal diagnosis identified acute HF hospitalization with a high positive predictive value. Systolic and diastolic ICD-10 diagnoses reliably identified heart failure with reduced ejection fraction and HFpEF when EF 50% was used as the cutoff.

10 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJ. Bradley Layton
J. Bradley Layton
WLWenhong Li
Wenhong Li
JYJiacan Yuan
Jiacan Yuan
JGJoshua P. Gilman
Joshua P. Gilman
DHDaniel B Horton
Daniel B Horton
SSSoko Setoguchi
Soko Setoguchi
Background: Heatwaves kill more people than floods, tornadoes, and earthquakes combined and disproportionally affect older persons and those with chronic conditions. Commonly used medications for chronic conditions, e.g., diuretics, antipsychotics disrupt thermoregulation or fluid/electrolyte balance and may sensitive patients to heat. However, the effect of heat-sensitizing medications and their interactions with heatwaves are not well-quantified. We evaluated effects of potentially heat-sensitizing medications in vulnerable older patients.Methods: US Medicare data were linked at the zip code level to climate data with surface air temperatures for June-August of 2007–2012. Patients were Medicare beneficiaries aged ≥65 years with chronic conditions including diabetes, dementia, and cardiovascular, lung, or kidney disease. Exposures were potentially heat-sensitizing medications including diuretics, anticholinergics, antipsychotics, beta blockers, stimulants, and anti-hypertensives. A heatwave was defined as ≥2 days above the 95thpercentile of historical zip code-specific surface air temperatures. We estimated associations of heat-sensitizing medications and heatwaves with heat-related hospitalization using self-controlled case series analysis.Results: We identified 9,721 patients with at least one chronic condition and heat-related hospitalization; 42.1% of these patients experienced a heatwave. Heatwaves were associated with an increase in heat-related hospitalizations ranging from 21% (95% CI: 7% to 38%) to 33% (95% CI: 14% to 55%) across medication classes. Several drug classes were associated with moderately elevated risk of heat-related hospitalization in the absence of heatwaves, with rate ratios ranging from 1.16 (95% CI: 1.00 to 1.35) to 1.37 (95% CI: 1.14 to 1.66). We did not observe meaningful synergistic interactions between heatwaves and medications.Conclusions: Older patients with chronic conditions may be at heightened risk for heat-related hospitalization due to the use of heat-sensitizing medications throughout the summer months, even in the absence of heatwaves. Further studies are needed to confirm these findings and also to understand the effect of milder and shorter heat exposure.

4 December 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
TOTetsu Ohnuma
Tetsu Ohnuma
KRKarthik Raghunathan
Karthik Raghunathan
SMSean Moore
Sean Moore
SSSoko Setoguchi
Soko Setoguchi
AEAlan R. Ellis
Alan R. Ellis
VKVijay Krishnamoorthy
Vijay Krishnamoorthy
Background: Gabapentinoids are commonly prescribed in perioperative multimodal analgesia protocols. Despite widespread use, the optimal dose to reduce opioid consumption while minimizing risks is unknown. We assessed dose-dependent effects of gabapentinoids on opioid consumption and postoperative pulmonary complications following total hip or knee arthroplasty (THA or TKA). We hypothesized that use of a gabapentinoid on the day of THA or TKA is associated with an increased risk of postoperative pulmonary complications in a dose-response fashion compared with the risk for patients who did not receive the drug. Methods: Using the Premier Database, we identified adults who underwent elective primary THA or TKA from 2009 to 2014. The exposure was receipt of a gabapentinoid (gabapentin or pregabalin) on the day of surgery. Gabapentin dose was categorized into 5 groups: none, 1 to 350, 351 to 700, 701 to 1,050, and >1,050 mg per day. Pregabalin dose was categorized into 4 groups: none, 1 to 110, 111 to 250, and >250 mg per day. The primary outcome was a composite of postoperative pulmonary complications, defined as respiratory failure, pneumonia, reintubation, pulmonary edema, noninvasive ventilation, or invasive mechanical ventilation. Results: Of 858,306 patients who underwent THA or TKA, 11.0% received gabapentin and 10.2% received pregabalin. The mean age (and standard deviation) of the patients was 65.6 ± 10.7 years, 39.6% were male, 78.2% were Caucasian, and 55.2% were covered by Medicare. In multilevel regression analysis, receipt of gabapentinoid at any dose on the day of surgery was associated with increased odds of postoperative pulmonary complications. Compared with no exposure to the drug being used by the particular group, all dose ranges of gabapentin and pregabalin were associated with greater odds of postoperative pulmonary complications (odds ratio, 95% confidence interval = 1.51, 1.40 to 1.63, for >1,050 mg of gabapentin and 1.81, 1.57 to 2.09, for >250 mg of pregabalin). We found no clinically meaningful associations between exposure to either gabapentin or pregabalin and perioperative opioid consumption or the length of the hospital stay. Conclusions: Exposure to gabapentinoids at any dose on the day of THA or TKA was associated with increased odds of postoperative pulmonary complications in a dose-response fashion, with minimal effects on perioperative opioid consumption. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 May 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
CDChintan V. Dave
Chintan V. Dave
GBGary M. Brittenham
Gary M. Brittenham
JCJeffrey L. Carson
Jeffrey L. Carson
SSSoko Setoguchi
Soko Setoguchi
Intravenous (IV) iron therapy has become more common in clinical practice, but concerns about risk for anaphylaxis remain. This retrospective study using Medicare data and a target trial emulation ... Visual Risks for Anaphylaxis With Intravenous Iron Formulations. Intravenous (IV) iron therapy has become more common in clinical practice, but concerns about risk for anaphylaxis remain. ... Background: The risks for anaphylaxis among intravenous (IV) iron products currently in use have not been assessed. Objective: To compare risks for anaphylaxis among 5 IV iron products that are use...

1 July 2018 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
ELEdward Chia-Cheng Lai
Edward Chia-Cheng Lai
PRPatrick Ryan
Patrick Ryan
YZYinghong Zhang
Yinghong Zhang
MSMartijn Schuemie
Martijn Schuemie
NHN Chantelle Hardy
N Chantelle Hardy
SSSoko Setoguchi
Soko Setoguchi
Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effectiveness and safety of medications commonly used in Asia using databases from individual Asian countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies is critical to this effort. Study design and setting: We converted data from the Japan Medical Data Center database, Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis and Reporting System, South Korea’s Ajou University School of Medicine database, and the US Medicare 5% sample to the Observational Medical Outcome Partnership common data model (CDM). Results: We completed and documented the process for the CDM conversion. The coordinating center and participating sites reviewed the documents and refined the conversions based on the comments. The time required to convert data to the CDM varied widely across sites and included conversion to standard terminology codes and refinements of the conversion based on reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. Because the native databases used international procedure coding systems for which mapping tables have been established, we were able to map >90% of diagnosis and procedure codes to standard terminology codes. Conclusion: The CDM established the foundation and reinforced collaboration for multinational pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest challenge, because of differences in health systems, cultures, and coding systems.

18 July 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
NKNana Koram
Nana Koram
MDMegan Delgado
Megan Delgado
JSJames H. Stark
James H. Stark
SSSoko Setoguchi
Soko Setoguchi
CLCynthia de Luise
Cynthia de Luise